Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

225.22 -10.35 (-4.39%)
Streaming Delayed Price Updated: 11:08 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Dow Struggles To Maintain Morning Gains
This morning's rally was short-lived, and by midday, the major indexes were trading back in the red amid looming recession anxieties. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Madrigal Shares Skyrocket After Successful NASH Study
Via Benzinga
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
Via Benzinga
Recap: Madrigal Pharmaceuticals Q1 Earnings
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug. 
Via The Motley Fool
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning
Good news can come in different forms. 
Via The Motley Fool
Why Is Viking Therapeutics (VKTX) Stock Up 67% Today?
Viking Therapeutics (VKTX) stock is taking off on Monday with heavy trading without any news from the biopharmaceutical company. 
Via InvestorPlace
AJRD Stock Alert: What to Know as L3Harris Technologies Acquires Aerojet Rocketdyne
Aerojet Rocketdyne (AJRD) stock is on the move today as investors react to a $4.7 billion deal with L3Harris Technologies (LHX). 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it. 
Via MarketBeat
Exposures Product Safety
Why Viking Therapeutics Stock Is Moving Alongside Madrigal Pharmaceuticals Shares Today
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Monday, in sympathy with Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), which announced a suc 
Via Benzinga
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?
Madrigal Pharmaceuticals (MDGL) stock is rocketing higher on Monday after sharing positive results from its NASH treatment. 
Via InvestorPlace
Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park
The company hit both of its goals in a Phase 3 study of a pill for the liver disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large... 
Via Benzinga
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
These two healthcare stocks could deliver market-crushing gains by year's end. 
Via The Motley Fool
Madrigal Pharmaceuticals: Q3 Earnings Insights
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
Via Benzinga
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch
Via Benzinga
Tough Slogging Ahead for Investors, Diversification is Important
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
Madrigal Pharmaceuticals: A "Best in Class" Biotech Buy
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.